

**PRODUCT DISRUPTION BRIEF**

# Baxter North Cove Facility (Marion, N.C.) (Updated Nov. 11)

The Baxter North Cove facility in Marion, N.C., was impacted by extensive flooding in western North Carolina.

## What's New

- **New:** Baxter shared it's expectations for increases in allocation levels across several IV product codes for direct customers and distributors in the U.S. via this [customer letter](#).
- **Webinar:** [Presentation here](#) from our Friday November 1 webinar where we featured an update from Baxter leadership and provider organization's conservation methodologies. ([Recording](#))
- **Extended Expiration Dates:** See [this Baxter customer letter](#) highlighting FDA authorization to extend expiration dates on the product codes listed within.
- **Baxter updates:** Baxter Hurricane Helene North Cove facility updates [website](#).
- **See here** for summary of Vizient and external resources
- **Continue deploying conservation strategies:** It is vital to begin implementing conservation strategies and revising clinical practice protocols to protect critical supplies required for patient care. [Go below for details](#).
- **IV fluid checklist and conservation strategies:** This [document](#) contains an IV fluid conservation checklist, oral rehydration guidance, considerations for resuscitation and total parenteral nutrition, and a comparison of the peritoneal dialysate solutions. Updated to include available premixed products of select essential medications.
- **Review Temporary Policies for Compounding Certain Parenteral Drug Products** [here](#)

## Background

Baxter's North Cove plant was affected by the heavy rain and storm surge caused by Hurricane Helene. The facility experienced water damage, and the plant was closed due to limited access caused by roadway collapse and flooding. The extent of the impact is still being assessed, and Baxter is working with local, state and federal officials to evaluate the situation and develop a plan to restore operations as quickly as possible. Baxter implemented a hurricane preparedness plan that included evacuation and product relocation measures; however, the facility was still impacted by a levee breach and bridge collapse.

The North Cove facility produces large volume intravenous (IV) fluids (e.g, saline, dextrose, lactated ringers) found on group purchasing organization (GPO) contracts, as well as peritoneal dialysis solutions that are not on GPO contracts. This manufacturing plant is a primary facility for large volume IV fluids used in the U.S., however Mexico and Spain are additional facilities Baxter has available as potential redundancy measures. Any capabilities of increasing production or leveraging alternate manufacturing sites are currently being assessed. Providers are urged to continue or implement conservation strategies. [Go below for details](#).

## Baxter IV product manufacturing locations

Category	Description	Primary manufacturing site	Potential alternate manufacturing sites	
Large volume IV fluids	IV fluids/irrigation ranging from 250 mL to 5,000 mL	North Carolina*	Mexico	Spain

\* Facility impacted by Hurricane Helene

## Baxter updates

- Baxter is implementing a U.S. protective allocation on the IV sets [identified within this customer letter](#). The allocation is based on customer historical ordering from April 1, 2024, through September 30, 2024, and will be effective on Monday, October 14, 2024

To learn more, please contact:  
**Theresa Dyer, Sr. Category Manager.,**  
[theresa.dyer@vizientinc.com](mailto:theresa.dyer@vizientinc.com).

As the nation's largest provider-driven health care performance improvement company, Vizient provides solutions and services that empower health care providers to deliver high-value care by aligning cost, quality and market performance. With analytics, advisory services and a robust sourcing portfolio, we help providers improve patient outcomes and lower costs.

- A dedicated email address that providers can use to contact Baxter with questions related to their IV solution questions and needs, specifically if they are in dire need of product, is [hurricanehelenesupport@baxter.com](mailto:hurricanehelenesupport@baxter.com)
- All products coming from Mexico and Spain are already coded for US and on Vizient agreements. (JB codes coming from Mexico and UE codes from Spain)
- Shang Hai imported IL Sodium injection will be dedicated to all Renal care. This allows all production from Mexico (1L) to free up for domestic acute care.
- Baxter implemented allocation measures to manage inventory effectively and minimize disruptions in patient care in the most recent [customer letter released Oct. 9](#).
- The company is also in the process of leveraging its global manufacturing network to mitigate potential supply impacts while efforts are made to fully restore manufacturing operations at the North Cove facility.
- Providers in need of assistance with Baxter Medical information can use the contact information below (THIS IS NOT TO BE USED FOR ADDITIONAL PRODUCT ALLOCATIONS AND IS ONLY FOR MEDICAL INFORMATION.):
  - Support fluids, nutrition and pharma products
    - Email: [medinfo@baxter.com](mailto:medinfo@baxter.com)
    - Tel: (800) 933-0303
  - Dialysis and renal related products
    - Email: [renalmedinfo@baxter.com](mailto:renalmedinfo@baxter.com)
    - Tel: (888) 736-2543

## Vizient updates

- Vizient has activated a command center and the Shortage Surveillance and Readiness Team (SSRT), which includes clinical, sourcing, analytics, government relations, communications and others, to fully assess the potential market impact.
- Vizient is communicating with Baxter to assess the potential supply constraints resulting from any production delay. Timelines and impact on current and future production at the North Cove facility are unknown at this time.
- Vizient is working with alternate manufacturers of potentially impacted products to assess their ability to supply and their capabilities to increase production if necessary.
- Vizient has communicated with pharmacy wholesalers to advocate and advise for pre-emptive allocations.

## Webinar:

- October 23 - The Assurance team discussed with providers the latest insights on IV fluid conservation and implementation strategies, [presentation](#). ([Recording](#))
- October 4 - Baxter representatives joined to share information regarding the impact of Hurricane Helene on its facility and provided resources to help navigate this situation. ([Recording](#))

## Drug shortages

- To access the dedicated site from the FDA for updates on this facility, [link](#).
- U.S. Department of Health and Human services letter to health care leaders, [Oct. 9](#).
- [This link](#) will highlight products that are currently in shortage and may be further impacted until North Cove resumes operations.

## Calls to action for provider customers

The most important call to action for all providers is CONSERVATION. Apply principles for conserving while maintaining safety. Strategies include using the smallest possible volume of IV fluids for the required indication, regularly reviewing patients receiving IV infusions and switching to alternative routes of administration if possible.

## Providers should do the following:

- Review the calls to action for hospitals, health systems, and clinics within the interconnected supply chain, [Drug Shortage Stewardship](#).
- Vizient encourages providers to utilize principles of [Drug Shortage Stewardship](#) to manage demand and limit drug shortage impact.
- Notify C-suite level executives of the impacted Baxter facility to ensure appropriate communication of potential supply constraints to the local media and associated medical boards.
- Based on the information provided on [Baxter's website](#) – review, revise and prepare to implement conservation strategies for fluids.

## Conservation/mitigation strategies

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.

- Providers should implement conservation and practice protocols immediately. Please see specific recommendations compiled by the American Society of Health-System Pharmacists (ASHP) and The University of Utah [here](#).
- Vizient has established the [Adult and Pediatric IV push medication reference](#) guide to conserve the use of IV fluids. This document provides guidance on how providers can take advantage of administering medications via IV push or slow IV injection; we have also noted where alternate routes – such as oral (PO) or intramuscular (IM) administration – are an option.
- Vizient is actively engaged with our IV suppliers to understand the current inventory levels and activate support for additional capacity. We will continue to monitor and report throughout this evolving disruption.
- This [document](#) contains an IV fluid conservation checklist, oral rehydration guidance, considerations for resuscitation and total parenteral nutrition, and a comparison of the peritoneal dialysate solutions.

## Alternate supplier and distributor updates

### Medical/surgical/pharmacy distributors

Vizient is actively engaged with our distribution suppliers and working to provide actionable information to include their specific [allocation](#) percentages. Based on efforts to increase manufacturing capacity at its other sites and current assessment of anticipated timing of inbound products and air shipments, Baxter notified in its most recent [press release Oct. 9](#) a change in allocations for distributors from 10 to 60%, effective Wednesday, Oct. 9. **NOTE:** After the effective date of a published increase in allocation, there will be a delay in product flow through the supply chain which could be up to 1 – 2 weeks.

#### For weekend emergencies:

##### Medline:

- Please contact your sales representative or contact Medline's help desk at (800) 216-5954 or email [helpdesk@medline.com](mailto:helpdesk@medline.com).

##### Cardinal:

- Monday – Friday: 24-hour support
- Saturday and Sunday: 7 a.m. to 7 p.m. Central Time
- Holidays: 7 a.m. to 7 p.m. Central Time (*limited staffing available*)
- Phone: (800) 964-5227
- Email: [medsupport@cardinalhealth.com](mailto:medsupport@cardinalhealth.com)

##### Owen's & Minor:

- Contact the O&M weekend customer service line at (800) 859-6803.

##### Cencora (AmerisourceBergen):

- Contact your local Cencora representative, or customer service at (800) 746-6273

##### McKesson - Weekend emergencies:

- Contact your local McKesson representatives.

##### Concordance - Weekend emergencies:

- [Representatives by region](#)

##### Henry Shein - Weekend emergencies:

- Contact your local Henry Schein representatives.

### Alternative IV solution contracted suppliers

	ICU Medical	Fresenius-Kabi	B. Braun
Offering	Large volume IV fluids	Large volume IV fluids	Large volume IV fluids
Contact	<a href="#">Jeffery Cole</a>	<a href="#">Joshua North</a>	<a href="#">Greg Sturdivant</a>

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.

<b>Website</b>	<a href="https://www.icumed.com/contact-us/">https://www.icumed.com/contact-us/</a>	<a href="https://www.fresenius-kabi.com/contact">https://www.fresenius-kabi.com/contact</a>	<a href="https://www.bbraunusa.com/en/about-us/contact/contact-form.html">https://www.bbraunusa.com/en/about-us/contact/contact-form.html</a>
<b>Protective allocation</b>	All large volume IV solution SKUs at 100%	All large volume IV solution SKUs at 100%	All large volume IV solution SKUs at 100%
<b>Taking new customers</b>	Reference customer letter dated Oct. 1	Pending confirmation	Pending confirmation
<b>Has excess inventory</b>	Reference customer letter dated Oct. 1	Pending confirmation	Pending confirmation

### Alternative oral hydration solution contracted suppliers

	Abbott	PepsiCo	Perrigo
<b>Contract</b>	EN0151	FD3676	EN0192
<b>Contact</b>	<a href="#">Kim Menges</a>	<a href="#">Adam Crow</a>	<a href="#">Tom Herzog</a>
<b>Direct ordering</b>	Yes	Yes	Yes
<b>Distribution partners*</b>	Cardinal, Medline, Owens & Minor, McKesson, and Cencora	Sysco and US Foods	Cardinal, Medline, McKesson and Cencora
<b>Ordering</b>	Pending	Taking new business. New Customers for direct orders: Activate and sign the letter of participation (LOP) through CPA.	Activate and sign the LOP through CPA.
	Coca-Cola		
<b>Contract</b>	FD3673		
<b>Contact</b>	<a href="#">Loren Scott</a>		
<b>Direct ordering</b>	Yes		
<b>Distribution partners*</b>	Sysco and US Foods		
<b>Ordering</b>	Activate and sign an LOP through CPA.		

\*Not all products/flavors are currently carried by listed distributors

### Alternative oral hydration solution non-contracted suppliers

	Liquid IV	Biolyte
<b>Contact</b>	<a href="#">Shannon Brienza</a>	<a href="#">Jim Jurgovan</a>
<b>Distribution partners*</b>	Cencora, Cardinal, Henry Schein, McKesson, Morris & Dickson	Distributed through McKesson. Cardinal, Morris and Dickson, Cencora
<b>Ordering</b>	Direct all communication to the contact.	Direct all communication to the contact.

## Appendix 1. Baxter North Cove facility impacted – IV solutions SKUs

### Baxter IV solution allocations

Baxter has increased allocations across multiple product lines listed by product category below; this is the [link](#) to the full customer letter containing the increased product level allocation.

Due to the vulnerable children's hospitals and populations, they serve, these facilities will have an increased allocation of 100%. Health systems that are not designated as a children's hospital but have key pediatric services, including pediatric emergency departments, NICUs or PICUs, should contact their Baxter representative with any questions about allocation levels. Information on peritoneal dialysis products will continue to be communicated separately to home patients and customers.

Product category	Allocation
BREVIBLOC premixed injection (esmolol hydrochloride) in sodium chloride	60%
Cardioplegic solution for cardiac perfusion	60%
Clinimix	100%
Dextrose (high concentration)	75%
Sterile water for injection (pharmacy bulk package)	90%

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.

Intravia empty bags	100%
Irrigation bag solutions	40%
Mini-Bag Plus	100%
ViaFlex IV solutions – large volume (saline and dextrose)*	60%
ViaFlex IV solutions – large volume (other)	40%
ViaFlex IV solutions – small volume	100%
Viaflo IV solutions – large volume	100%

\*Represents high-demand IV solution codes

## Impacted IV solutions SKUs and cross-references to known alternatives

Table 1 is a detailed list of the top utilized IV solutions product codes, NDCs, Baxter current allocation amount and its known alternatives. For a detailed list of all impacted IV solution product, leverage this [link](#).

**Table 1**

NDC	Product code	Description	B. Braun product code	Becton Dickinson product code	Fresenius Kabi product code	ICU Medical product code
00338001702	2B0062Q	Dextrose 5% inj, USP 250 mL migrated	L5102	1727172005	624674	07922-02
00338001703	2B0063Q	Dextrose 5% inj, USP 500 mL migrated	L5101	1727172006	624675	07922-03
00338001704	2B0064X	Dextrose 5% in, USP 1,000 mL migrated	L5100	1727172007	624610	07922-09
00338008904	2B1064X	5% dex and 0.9% sod chl inj, USP	L6100	N/A	870174	07941-09
00338008504	2B1074X	5% dex and 0.45% sod chl inj, USP	L6120	N/A	869110	07926-09
00338004902	2B1322Q	Sod chlor 0.9% inj, USP ViaFlex plastic 250 mL migrated	L8002	1727170105	623174	07983-02
00338004903	2B1323Q	Sod chlor 0.9% inj, USP ViaFlex plastic 500 mL migrated	L8001	1727170106	623175	07983-03
00338004904	2B1324X	Sod chlor 0.9% inj, USP ViaFlex 1,000 mL migrated	L8000	1727170107	623176	07983-09
00338011702	2B2322Q	Lactated ringer's inj, USP	L7502	1727171005	964174	07953-02
00338011703	2B2323Q	Lactated ringer inj, USP via flex plastic container 500 mL	L7501	1727171006	964175	07953-03
00338011704	2B2324X	Lactated ringer inj, USP 1,000 mL ViaFlex container	L7500	1727171007	964176	07953-09
00338022104	2B2544X	Plasma-Lyte A inj, pH 7.4 multiple	L7070	N/A	389100	07670-09
00338004747	2B7127	0.9% sod chl irrig, USP 3,000 mL Uromatic container	R8206	N/A	N/A	07972-08
00338004727	2B7477	0.9% sod chl irrig, USP, 3,000 mL Arthromatic	R8206	N/A	N/A	07972-08
00338013727	2B7487	Lactated ringers irrig, 3,000 mL Arthromatic	R8306	N/A	N/A	07828-08

## Appendix 2. Baxter North Cove facility impacted – dialysis SKUs

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.

## Baxter dialysis allocations

All products produced out of Baxter's North Cove facility will be placed on allocation identified in the [Baxter customer letter dated Oct. 3](#). The allocation amounts will apply to direct orders through Baxter based on historical purchases from March 1, 2024, through August 31, 2024. All new medically necessary patient exceptions must be submitted over the phone to HomeCare Services at (800) 284-4060, **THIS IS FOR DIALYSIS PRODUCTS ONLY**.

NDC	Product code	Description
0941067952	5B4984	Extraneal PD-2 2l/2l UltraBag
0941067953	5B4986	Extraneal PD-2 2.5l/3.0l UltraBag
0941042455	5B9757	Dianeal low ca 1.5% dex 3l/5l UltraBag (2.5 meq/l)
0941043055	5B9758	Dianeal low ca 2.5% dex 3l/5l UltraBag (2.5 meq/l)
0941043355	5B9759	Dianeal low ca 4.25% dex 3l/5l UltraBag (2.5 meq/l)
0941042451	5B9765P	Dianeal low ca 1.5% dex1.5l/2l UltraBag (2.5 meq/l)
0941042452	5B9766	Dianeal low ca 1.5% dx 2l/2l UltraBag (2.5 meq/l)
0941042453	5B9768P	Dianeal low ca 1.5% dex2.5l/3l UltraBag (2.5 meq/l)
0941043051	5B9775P	Dianeal low ca 2.5% dex 1.5l/2 l UltraBag(2.5meq/l)
0941043052	5B9776	Dianeal low ca 2.5% dex 2l/2l UltraBag (2.5 meq/l)
0941043053	5B9778P	Dianeal low ca 2.5% dex 2.5/3l UltraBag (2.5 meq/l)
0941043351	5B9795P	Dianeal low ca 4.25% dex 1.5l/ 2l UltraBag (2.5meq/l)
0941043352	5B9796	Dianeal low ca 4.25%dex 2l/2l UltraBag (2.5 meq/l)
0941043353	5B9798P	Dianeal low ca 4.25% dex 2.5/ 3l UltraBag (2.5 meq/l)
0941042655	5B9857	Dianeal PD-2 solution 1.5% dex 3l/5l UltraBag
0941042755	5B9858	Dianeal PD-2 solution 2.5% dex 3l/5l UltraBag
0941-0429-55	5B9859	Dianeal PD-2 solution 4.25% dex 3l/5l UltraBag
0941042652	5B9866	Dianeal PD-2 solution 1.5% dex 2l/2l UltraBag
0941-0426-53	5B9868P	Dianeal PD-2 solution 1.5% dex 2.5l/3l UltraBag
0941042752	5B9876	Dianeal PD-2 solution 2.5% dex 2l/2l UltraBag
0941042753	5B9878P	Dianeal PD-2 solution 2.5% dex 2.5l/3l UltraBag
0941-0429-52	5B9896	Dianeal PD-2 solution 4.25% de x 2l/2l UltraBag
0941-0429-53	5B9898P	Dianeal PD-2 solution 4.25% dex 2.5l/3l UltraBag
0941040906	L5B4825	Dianeal low cal 1.5% dex 2l/2 l PD solution
0941040907	L5B4826	Dianeal low cal 1.5% dex 5l/6l (sys 2)
0941067906	L5B4974	Extraneal PD-2 (icodextrin) pd soln (2l/3l)
0941067905	L5B4976	Extraneal PD-2 (icodextrin) pd soln (2.5l/3l)
0941041105	L5B5163	Dianeal PD-2 1.5% dex 1l/1l (sys 2)
0941041106	L5B5166	Dianeal PD-2 1.5% dex 2l/3l (sys 2)
0941041104	L5B5169	Dianeal PD-2 1.5% dex 3l/3l (sys 2)
0941041305	L5B5173	Dianeal PD-2 2.5% dex 1l/1l (sys 2)
0941041306	L5B5177	Dianeal PD-2 2.5% dextrose (2l/2l)
0941041304	L5B5179	Dianeal PD-2 2.5% dex 3l/3l (sys 2)
0941041505	L5B5183	Dianeal PD-2 4.25% dex 1l/1l (sys 2)
0941041506	L5B5187	Dianeal PD-2 4.25% dex 2l/3l (sys 2)
941041504	L5B5189	Dianeal PD-2 4.25% dex 3l/3l (sys 2)
0941041107	L5B5193	Dianeal PD-2 1.5% dextrose (5l/6l)

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.

NDC	Product code	Description
0941-0413-07	L5B5194	Dianeal PD-2 2.5% 5l/6l (sys 2)
0941041507	L5B5195	Dianeal PD-2 4.25% dex 5l/6l (sys 2)
0941045705	L5B5202	Dianeal low cal 2.5% dex 5l/6l (sys 2) (2.5 meq/l)
0941045905	L5B5203	Dianeal low ca 4.25% dex 5l/6l (sys 2) (2.5% meq/l)
0941041111	L5B9710	Dianeal PD-2 1.5% dex 6l/6l (sys 2)
0941041301	L5B9711	Dianeal PD-2 2.5% dex 6l/6l (sys 2)
0941041501	L5B9712	Dianeal PD-2 4.25% dex 6l/6l (sys 3)
0941045708	L5B9727	Dianeal low cal (2.5 meq/l) pd soln 2.5% dex (2l/3l)
0941045908	L5B9747	Dianeal low cal 4.25% dex 2l/3 l pd solution
0941040901	L5B9770	Dianeal low ca 1.5% dex 6l/6l (sys 2) (2.5 meq/l)
0941045701	L5B9771	Dianeal low cal 2.5% dex 6l/6l (sys 2) (2.5 meq/l)
0941045901	L5B9772	Dianeal low ca 4.25% dex 6l/6l (sys 2) (2.5 meq/l)
0941-0409-05	L5B9901	Dianeal low ca 1.5% 3l/3l (sys 2) (2.5 meq/l)
0941045702	L5B9902	Dianeal low cal 2.5% dex 3l/3l (sys 2) (2.5 meq/l)
0941045902	L5B9903	Dianeal low cal 4.25% dex 3l/3l (sys 2) (2.5 meq/l)

### Appendix 3. Allocation Update – Premix IV Drug Products

Baxter announced that they are implementing a protective 125% allocation on select premix products available in their portfolio due to higher-than-normal demand secondary to the intravenous fluid shortage, through a [customer letter dated October 17, 2024](#). The 125% allocation is based on historical ordering made between April 2024-September 2024. Any quantity that exceeds the allocation will be automatically cancelled by Baxter. For questions, please contact your Baxter Sales Representative or Baxter’s Center for Service at 1-888-229-0001. Products that are affected are listed in the table below.

Product	Total Strength/Total Volume	Product Code	NDC
Cardene IV (nicardipine hydrochloride in 0.86% Sodium Chloride)	20 mg/200 mL	2G3443	43066-009-10
Cardene IV (nicardipine hydrochloride in 0.83% Sodium Chloride)	40 mg/200 mL	2G3444	43066-016-10
Cardene IV (nicardipine hydrochloride in 0.86% Sodium Chloride NOVAPLUS)	20 mg/200 mL	2G3445	43066-021-10
Cardene IV (nicardipine hydrochloride in 0.83% Sodium Chloride NOVAPLUS)	40 mg/200 mL	2G3446	13066-024-10
Nexterone (amiodarone HCl) premixed injection	150 mg/100 mL	2G3451	43066-150-10
Nexterone (amiodarone HCl) premixed injection	360 mg/200 mL	2G3450	43066-360-20
Norepinephrine bitartrate in 5% dextrose injection	4 mg/250 mL	EZPE7748	0338-0112-20
Norepinephrine bitartrate in 5% dextrose injection	8 mg/250 mL	EZPE7788	0338-0108-20
Cefazolin injection, USP	1 g/50 mL	2G3503	0338-3503-41
Cefazolin injection, USP	2 g/100 mL	2G3508	0338-3508-41
Cefepime injection	1 g/50 mL	2G3578	0338-1301-41
Cefepime injection	2 g/100 mL	2G3579	0338-1301-48
Ceftriaxone injection, USP (in 5% Dextrose)	1 g/50 mL	2G3504	0338-5002-41
Ceftriaxone injection, USP (in 5% Dextrose)	2 g/50 mL	2G3505	0338-5003-41
Daptomycin in 0.9% Sodium Chloride injection	350 mg/50 mL	2G3593	0338-0712-24
Daptomycin in 0.9% Sodium Chloride injection	500 mg/50 mL	2G3594	0338-0714-24

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE’S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL’S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.

Product	Total Strength/Total Volume	Product Code	NDC
Daptomycin in 0.9% Sodium Chloride injection	700 mg/100 mL	2G3595	0338-0716-12
Daptomycin in 0.9% Sodium Chloride injection	1,000 mg/100 mL	2G3596	0338-0718-12
Nafcillin injection, USP	2 g/100 mL	2G3556	0338-1019-48
Oxacillin injection, USP	2 g/50 mL	2G3539	0338-1015-41
Penicillin G Potassium injection, USP	2,000,000 units/50 mL	2G3543	0338-1023-41
Penicillin G Potassium injection, USP	3,000,000 units/50 mL	2G3544	0338-10205-41
Vancomycin injection, USP (in 5% Dextrose)	500 mg/100 mL	2G3551	0338-3551-48
Vancomycin injection, USP (in 5% Dextrose	750 mg/150 mL	2G3580	0338-3580-48
Vancomycin injection, USP (in 5% Dextrose	1 g/200 mL	2G3552	0338-3552-48
Vancomycin injection, USP (in 5% Dextrose	1.25 g/250 mL	2G3557	0338-0122-04
Vancomycin injection, USP (in 5% Dextrose	1.5 g/300 mL	2G3558	0338-0124-04
Vancomycin injection, USP (in 0.9% Sodium Chloride)	500 mg/100 mL	2G3590	0338-3581-01
Vancomycin injection, USP (in 0.9% Sodium Chloride)	750 mg/150 mL	2G3591	0338-3582-01
Vancomycin injection, USP (in 0.9% Sodium Chloride)	1 g/200 mL	2G3592	0338-3583-01
Zosyn (piperacillin and tazobactam) injection	2.25 g/50 mL	2G3582	0338-9632-24
Zosyn (piperacillin and tazobactam) injection	3.375 g/50 mL	2G3583	0338-9636-24
Zosyn (piperacillin and tazobactam) injection	4.5 g/100 mL	2G3524	0338-9638-12

## Summary of resources

### Vizient resources

- [NEW! IV fluid checklist and conservation strategies](#)
- [Adult and pediatric IV push medication reference](#)
- [Webinar](#)

### External resources

- ASN: [Interim strategies for peritoneal dialysis \(PD\) solution use for prevalent patients undergoing PD](#)
- ASA: [Suggested Actions on Conservation of IV Solutions During Ongoing Shortage](#)
- ASPEN: [Resources for IV Fluid Shortages](#)
- HHS: [Letter to Health Care Leaders and Stakeholders on Impacts of Hurricane Helen from Secretary Becerra](#)
- FDA: [Hurricane Helene: Baxter's manufacturing recovery in North Carolina](#)
- FDA: [Temporary Polices for Compounding Certain Parenteral Drug Products](#)
- ASHP: [Small- and Large-Volume Fluid Shortages – Suggestions for Management and Conservation](#)
- NHIA: [Guidance for Addressing Product Shortages during Disruptions in Manufacturing](#)
- Review CDC HAN Advisory for IV and PD Solutions [here](#)

## Additional resources

[Supply assurance webpage](#); [Vizient Newsroom](#)



Want to receive weekly Supply Assurance updates?

Update your preferences through our [Subscription Manager](#) by selecting Supply Assurance Weekly Digest.

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.



Questions? Contact [disasterresponse@vizientinc.com](mailto:disasterresponse@vizientinc.com), [pharmacyquestions@vizientinc.com](mailto:pharmacyquestions@vizientinc.com), [novaplus@vizientinc.com](mailto:novaplus@vizientinc.com).

**DISCLAIMER:** THE INFORMATION CONTAINED IN THIS DOCUMENT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY AND IS IN NO WAY INTENDED TO BE A SUBSTITUTE FOR OR IN ANY MANNER TO BE CONSTRUED AS MEDICAL OR CLINICAL ADVICE. VIZIENT IS COMPILING INFORMATION AND EMERGING PRACTICES FROM MEMBERS TO AID IN KNOWLEDGE TRANSFER DURING CRITICAL SUPPLY EVENTS. THE INFORMATION CONTAINED HEREIN HAS NOT BEEN INDEPENDENTLY VERIFIED, RESEARCHED, OR INVESTIGATED AND SHOULD NOT BE CONSTRUED AS ADVICE OR A RECOMMENDATION. DECISIONS REGARDING WHETHER AND HOW TO UTILIZE ANY OF THESE PRACTICES SHOULD BE MADE BY HEALTH CARE PROVIDERS, AT THEIR OWN RISK, WITH CONSIDERATION OF INDIVIDUAL CIRCUMSTANCES. AS INFORMATION IS CHANGING RAPIDLY, VIZIENT ENCOURAGES YOU TO ALWAYS REFER TO THE CDC, YOUR STATE'S DEPARTMENT OF HEALTH, AND YOUR LOCAL PUBLIC HEALTH AUTHORITY FOR GUIDANCE. VIZIENT DOES NOT PROVIDE LEGAL, REGULATORY, OR MEDICAL ADVICE AND DISCLAIMS LIABILITY OR RESPONSIBILITY FOR THE ACCURACY, COMPLETENESS, AND/OR CLINICAL EFFICACY AND SAFETY FOR THE PRODUCTS OR PROCESSES CONTAINED HEREIN. MEMBERS SHOULD SEEK THEIR LEGAL COUNSEL'S ADVICE ON LOCAL, STATE, AND FEDERAL LEGAL/REGULATORY MATTERS.